-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $48

Benzinga·09/04/2026 18:34:18
Listen to the news
UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $42 to $48.